International Stem Cell Corp. (ISCO) Reports Significant Improvement in Subsidiary Product Sales and Customer Base
International Stem Cell Corp., a biotech company focused on therapeutic applications of human parthenogenetic stem cells, today announced that its wholly owned subsidiary Lifeline Cell Technology achieved 35 percent growth in 2011 first-quarter product sales, and gained more than 200 new customers over the year prior. The company attributes the improvement to more than 30 new product introductions, as well as the development of worldwide distribution channels in Japan, India, Taiwan, South Korea and Singapore. Lifeline also noted significant progress in its growth strategy, which includes expanding product applications into manufacturing human tissues and cells for clinical use. The company…